Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412214 | 0.86 | TACR1 (0.35) | MAPK1DHFR | |
| SCHEMBL6428528 | 0.86 | GALR1 (0.35) | MAPK1DHFR | |
| SCHEMBL6819318 | 0.85 | MAPK1 (0.33) | MAPK1DHFR | |
| SCHEMBL5554034 | 0.85 | GALR1 (0.38) | MAPK1DHFR | |
| SCHEMBL6607370 | 0.85 | GALR1 (0.39) | MAPK1DHFR | |
| SCHEMBL5553512 | 0.84 | MAPK1 (0.39) | MAPK1KCNH3 | |
| SCHEMBL6428837 | 0.84 | ALDH1A1 (0.35) | MAPK1DHFR | |
| SCHEMBL6208797 | 0.83 | SLC6A3 (0.35) | MAPK1 | |
| SCHEMBL6016949 | 0.83 | SMN1; SMN2 (0.43) | MAPK1 | |
| SCHEMBL5553495 | 0.83 | MAPK1 (0.34) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | claimed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | MAPK1 370/4885PDE4A 3288/4885DHFR 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.